)
Visual
test
Corline Biomedical
Corline Biomedical (CLBIO) investor relations material
Corline Biomedical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary17 Feb, 2026
Executive summary
Achieved key milestone with first commercial use of CHS™ in a US-launched product, driving entry into the fast-growing PFA market for cardiac arrhythmia treatment.
Strategic focus on scaling production and strengthening partnerships, notably with Kardium, to support anticipated volume growth and customer activity in 2026.
Financial highlights
Net sales for Q4 2025 were 2,104 KSEK, up slightly from 2,012 KSEK in Q4 2024; full-year net sales were 7,651 KSEK, down from 9,775 KSEK year-over-year.
Q4 result after financial items was -5,027 KSEK (improved from -14,161 KSEK); full-year result after financial items was -14,714 KSEK (improved from -23,194 KSEK).
No one-time items affected 2025 results, compared to -9,992 KSEK in 2024.
Cash and cash equivalents at year-end were 20.6 MSEK, up from 17.7 MSEK.
Equity at year-end was 93,759 KSEK, with a solidity of 95%.
Outlook and guidance
Expecting volume growth and increased customer activity in 2026, supported by commercial agreements and regulatory tailwinds in the US.
Ongoing investments in production capacity and quality systems to meet future demand and regulatory requirements.
What revenue impact from 20x Kardium volume?
CHS™ Growth: US medtech customer pipeline
How does Globe's PFA differentiation impact Corline?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Corline Biomedical
- Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth.CLBIO
Q3 202518 Nov 2025 - Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales.CLBIOQ2 202526 Aug 2025
- Sharply reduced costs and strategic focus position Corline for growth and profitability by 2025.CLBIOQ3 202413 Jun 2025
- Revenue down, losses widened, but US launch and new projects drive future potential.CLBIOQ2 202413 Jun 2025
- Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism.CLBIOQ1 20256 Jun 2025
- 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®.CLBIOQ4 20245 Jun 2025
Next Corline Biomedical earnings date
Q1 20268 May, 2026
Corline Biomedical
Next Corline Biomedical earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage